From Genes to Pathways to Novel Drugs For Multiple Sclerosis
Mission_MS is developing leads for novel medications to treat Multiple Sclerosis (MS), a progressive autoimmune and neurodegenerative disease that damages nerve cells and eventually leads to severe disability. The disease is first diagnosed at age 25-35 and currently, there is no cure. Therefore, lifelong treatment to lower disease activity is required. Given a total of 2,5 million MS patients worldwide, the medical costs for treating the disease as well as related societal costs due to loss of productivity are enormous.
Mission_MS aims to modulate key genes capable of stimulating myelination and nerve cell repair. Their use as drug target will be based on insights into disease mechanism(s), inferred from the function of these risk genes identified in families with MS. With an expected total of 30 high-effect MS risk genes identified, Mission_MS will be capable of setting up a pipeline of drug targets and to generate an IP portfolio of drug target-compound combinations focused on myelination/nerve cell repair and with potential of stopping the disease process completely.
Mission_MS consists of a highly experienced team bringing together extensive expertise in the fields of human genetics (Tineke Banda, M.Sc. ; Geert Poelmans M.D. Ph.D.), molecular and cellular biology (Wiebe Kruijer, Ph.D., prof. dr. em.), MS neurology (Sjef Jongen, M.D., Ph.D.) and MS nursing and patient-related issues (Marco Heerings, MANP, Ph.D. candidate) from Drug Target ID (DTID) B.V. and Radboudumc.
- Venture Challenge Spring 2019